Roche (OTCMKTS:RHHBY) Stock Rating Lowered by Hsbc Global Res

Roche (OTCMKTS:RHHBY) was downgraded by analysts at Hsbc Global Res from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

A number of other research firms have also issued reports on RHHBY. UBS Group raised Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. HSBC downgraded shares of Roche from a “buy” rating to a “hold” rating in a research note on Monday. Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a report on Thursday, January 30th. Finally, Morgan Stanley started coverage on shares of Roche in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

Roche Stock Performance

OTCMKTS:RHHBY opened at $40.66 on Monday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26. Roche has a 52 week low of $29.20 and a 52 week high of $44.31. The company has a fifty day simple moving average of $40.74 and a two-hundred day simple moving average of $38.61.

Institutional Investors Weigh In On Roche

A number of hedge funds and other institutional investors have recently modified their holdings of RHHBY. Brooklyn Investment Group boosted its holdings in shares of Roche by 36.6% in the 4th quarter. Brooklyn Investment Group now owns 1,354 shares of the company’s stock valued at $48,000 after purchasing an additional 363 shares during the last quarter. Verity Asset Management Inc. boosted its holdings in Roche by 26.8% in the fourth quarter. Verity Asset Management Inc. now owns 8,036 shares of the company’s stock valued at $280,000 after acquiring an additional 1,697 shares during the last quarter. HighPoint Advisor Group LLC grew its position in Roche by 2.8% during the fourth quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company’s stock valued at $387,000 after acquiring an additional 304 shares during the period. Fulton Bank N.A. increased its stake in Roche by 2.6% during the first quarter. Fulton Bank N.A. now owns 12,620 shares of the company’s stock worth $518,000 after acquiring an additional 314 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Roche by 59.5% in the 1st quarter. GAMMA Investing LLC now owns 12,850 shares of the company’s stock worth $529,000 after purchasing an additional 4,794 shares during the period.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.